Patents Assigned to Spectrum Pharmaceuticals, Inc.
  • Patent number: 10022421
    Abstract: Disclosed are methods of treating a chemotherapy-resistant cancer, of treating a cholangiocarcinoma, of treating a metastatic carcinoma, and of treating a transition cell urothelial carcinoma by administering a therapeutically effective amount of an endothelin B (ETB) receptor agonist and a chemotherapeutic agent to a subject afflicted with such a cancer.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: July 17, 2018
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Anthony W. Tolcher, Luigi Lenaz
  • Publication number: 20180177783
    Abstract: The present invention relates to compositions and methods for treating lymphoma in a subject in need thereof, said methods comprising administering to the patient in need thereof a therapeutically effective amount of a combination of belinostat and pralatrexate, wherein said therapeutically effective amount results in a synergistic antiproliferative effect on cancer cell growth.
    Type: Application
    Filed: June 14, 2016
    Publication date: June 28, 2018
    Applicant: Spectrum Pharmaceuticals, Inc.
    Inventor: Guru Reddy
  • Patent number: 9713616
    Abstract: Compositions comprising a calcium salt of L-leucovorin may be prepared that have a higher concentration of L-leucovorin than may be prepared using racemic leucovorin under similar conditions. Thus, some pharmaceutical compositions described herein may comprise a calcium salt of L-leucovorin at a relatively high concentration, such as at least about 15 mg/mL. Such a composition may be a stable aqueous solution, and may have near physiological pH, such as about 6 to about 8. Some pharmaceutical compositions may be substantially free of D-leucovorin, and may contain either: a) no EDTA, or b) less than about 1 mg/ml of EDTA. These compositions may be prepared, for example, by sonicating a mixture comprising the solid calcium salt of L-leucovorin and water. In some compositions, a calcium salt of L-leucovorin may be sufficiently soluble that it does not precipitate when it is injected.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: July 25, 2017
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Pramod Kumar Gupta, Bahman Shimiaei, Shaofeng Xie
  • Patent number: 9511091
    Abstract: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: December 6, 2016
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Rudi E. Moerck, Timothy Malcome Spitler, Edward A. Schauer, Jan Prochazka
  • Patent number: 9308235
    Abstract: Disclosed are methods of treating a chemotherapy-resistant cancer, of treating a cholangiocarcinoma, of treating a metastatic carcinoma, and of treating a transition cell urothelial carcinoma by administering a therapeutically effective amount of an endothelin B (ETB) receptor agonist and a chemotherapeutic agent to a subject afflicted with such a cancer.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: April 12, 2016
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Anthony W. Tolcher, Luigi Lenaz
  • Patent number: 9295666
    Abstract: Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: March 29, 2016
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijnen, Dorla Mirejovsky, Guru Reddy, Luigi Lenaz
  • Patent number: 9000031
    Abstract: The present specification provides compositions comprising a thioxanthone-based autophagy inhibitor and/or a cancer therapeutic autophagy inducing compound, pharmaceutical kits comprising these compositions, and methods of treating cancer using such compounds, compositions and kits. Additionally, the present specification provides methods of treating cancer using a thioxanthone-based autophagy inhibitor and a radiotherapy.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: April 7, 2015
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Steffan Nawrocki, Jennifer Carew, Guru Reddy
  • Patent number: 8961917
    Abstract: The present invention is a method of producing a lanthanum carbonate hydroxide or lanthanum oxycarbonate which has improved properties. The method involves the use of a water soluble lanthanum and a water soluble non-alkali metal carbonate or bicarbonate. The resulting material can be used as a phosphate binder individually or for treating patients with hyperphosphatemia.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: February 24, 2015
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Ashok Yeshwant Gore, Edward A. Schauer, Matthew Stewart, Ramsharan Singh
  • Patent number: 8957014
    Abstract: Methods to sensitize tumor cells to radiation therapy through the administration of an endothelin agonist such as the ETB agonist IRL1620.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: February 17, 2015
    Assignees: Spectrum Pharmaceuticals, Inc., The Board of Trustees of the University of Illinoise
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • Patent number: 8852543
    Abstract: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: October 7, 2014
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Rudi E. Moerck, Timothy Malcome Spitler, Edward A. Schauer, Jan Prochazka
  • Publication number: 20140288143
    Abstract: Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, bladder cancer treatments include the intravesical administration of apaziquone immediately following transurethral resection. Also disclosed are therapeutic compositions comprising an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.
    Type: Application
    Filed: February 5, 2014
    Publication date: September 25, 2014
    Applicant: Spectrum Pharmaceuticals, Inc.
    Inventors: Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijnen, Luigi Lenaz, Shanta Chawla, Mario Beer
  • Patent number: 8815953
    Abstract: The present invention provides topical formulations containing a vitamin K analog, e.g., menadione, that deliver a uniform, therapeutically effective concentration of the vitamin K analog to the skin in a vehicle which is stable, non-irritating, non-drying and cosmetically acceptable. These topical formulations are useful for the treatment and prevention of dermatological conditions associated with inflammation, particularly, dermatological conditions resulting from anti-EGFR therapies.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: August 26, 2014
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Christopher G. Salentine, Kieran O'Donoghue
  • Publication number: 20140161702
    Abstract: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.
    Type: Application
    Filed: January 7, 2014
    Publication date: June 12, 2014
    Applicant: SPECTRUM PHARMACEUTICALS, INC.
    Inventors: Rudi E. Moerck, Timothy Malcome Spitler, Edward A. Schauer, Jan Prochazka
  • Publication number: 20140161885
    Abstract: The present invention is a method of producing a lanthanum carbonate hydroxide or lanthanum oxycarbonate which has improved properties. The method involves the use of a water soluble lanthanum and a water soluble non-alkali metal carbonate or bicarbonate. The resulting material can be used as a phosphate binder individually or for treating patients with hyperphosphatemia.
    Type: Application
    Filed: December 12, 2013
    Publication date: June 12, 2014
    Applicant: SPECTRUM PHARMACEUTICALS, INC.
    Inventors: Ashok Yeshwant Gore, Milind Dixit, Ravichandran Mahalingam, Edward A. Schauer, Matthew Stewart, Rajendra Tandale, Ramsharan Singh
  • Patent number: 8734818
    Abstract: The present specification discloses tetrahydroindolone derivatives or analogues and methods for treating cognitive/attention deficit disorders using such tetrahydroindolone derivatives and analogues.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: May 27, 2014
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Alvin J. Glasky, David B. Fick, David R. Helton
  • Patent number: 8729023
    Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: May 20, 2014
    Assignees: Spectrum Pharmaceuticals, Inc., The Board of Trustees of the University of Illinois
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • Patent number: 8715603
    Abstract: Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: May 6, 2014
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Rudi E. Moerck, Timothy Malcome Spitler, Edward A Schauer, Jan Prochazka
  • Publication number: 20140106003
    Abstract: The present specification provides compositions comprising a thioxanthone-based autophagy inhibitor and/or a cancer therapeutic autophagy inducing compound, pharmaceutical kits comprising these compositions, and methods of treating cancer using such compounds, compositions and kits. Additionally, the present specification provides methods of treating cancer using a thioxanthone-based autophagy inhibitor and a radiotherapy.
    Type: Application
    Filed: August 6, 2013
    Publication date: April 17, 2014
    Applicant: SPECTRUM PHARMACEUTICALS, INC.
    Inventors: Steffan Nawrocki, Jennifer Carew, Guru Reddy
  • Publication number: 20140073680
    Abstract: Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.
    Type: Application
    Filed: August 30, 2013
    Publication date: March 13, 2014
    Applicant: Spectrum Pharmaceuticals, Inc.
    Inventors: Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijnen, Dorla Mirejovsky, Guru Reddy, Luigi Lenaz
  • Patent number: 8648108
    Abstract: Anti-cancer coating compositions comprising 3-hydroxymethyl-5-aziridinyl-1-1-methyl-2-[1H-indole-4,7-dione]propenol (E09) are disclosed. More specifically, the coating compositions comprise EO9 and a formulation vehicle. The formulation vehicle improves the solubility and stability of EO9. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: February 11, 2014
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijen